TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program

NCT ID: NCT00569491

Last Updated: 2008-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

2585 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TAXUS ARRIVE study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAXUS Express 2™

TAXUS Express™ Paclitaxel-Eluting Coronary Stent System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inappropriate Patients Criteria:

* Known sensitivity to paclitaxel.
* Known allergy to stainless steel.
* Patients in whom antiplatelet and / or anticoagulant therapy is contraindicated.
* Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.
* Patients with unresolved vessel thrombus at the lesion site.
* Patients with coronary artery reference vessel diameters \< 2.5 mm or \> 3.75 mm.
* Patients with lesions located in the left main coronary artery, ostial lesions, or lesions located at a bifurcation.
* Patients with diffuse disease or poor overflow distal to the identified lesions.
* Patients with tortuous vessels in the region of the obstruction or proximal to the lesion.
* Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boston Scientific

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eileen Rose, MS

Role: STUDY_DIRECTOR

Boston Scientific Corporation

John M Lasala, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

David A Cox, MD

Role: PRINCIPAL_INVESTIGATOR

Lehigh Valley Physician Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Advanced Cardiac Specialists

Gilbert, Arizona, United States

Site Status

Cardiology Associates of NEA

Jonesboro, Arkansas, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Salinas Valley Memorial Hospital

Salinas, California, United States

Site Status

Good Samaritan

San Jose, California, United States

Site Status

Little Company of Mary Hospital

Torrance, California, United States

Site Status

Poudre Valley Hospital

Fort Collins, Colorado, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Advanced Clinical Research Group, LLC

Juniper, Florida, United States

Site Status

Florida Heart Institute

Orlando, Florida, United States

Site Status

Tallahassee Memorial Hospital

Tallahassee, Florida, United States

Site Status

Georgia Heart and Vascular Center

Macon, Georgia, United States

Site Status

Alexian Brothers Medical Center

Elk Grove, Illinois, United States

Site Status

Lutheran Hospital/NIRA

Fort Wayne, Indiana, United States

Site Status

St Francis Hospital

Indianapolis, Indiana, United States

Site Status

Genesis Medical Center

Davenport, Iowa, United States

Site Status

Our Lady of Lourdes

Lafayette, Louisiana, United States

Site Status

Willis Knighton Medical Center

Shreveport, Louisiana, United States

Site Status

Northeast Cardiology Associates

Bangor, Maine, United States

Site Status

Maine Medical Center

Portland, Maine, United States

Site Status

Delmarva Heart Research Foundation, Inc

Salisbury, Maryland, United States

Site Status

Regional Cardiology Associates

Grand Blanc, Michigan, United States

Site Status

Metro Cardiology Consultants

Coon Rapids, Minnesota, United States

Site Status

Research Medical Center

Kansas City, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Cardiovascular Consultants of Nevada

Las Vegas, Nevada, United States

Site Status

Morristown Memorial

Morristown, New Jersey, United States

Site Status

Westchester County Medical Center

Valhalla, New York, United States

Site Status

Asheville Cardiology Associates, PA

Asheville, North Carolina, United States

Site Status

Mid-Carolina Cardiology Presbyterian Hospital

Charlotte, North Carolina, United States

Site Status

Pitt County Memorial Hospital

Greenville, North Carolina, United States

Site Status

WakeMed - Wake Heart Associates

Raleigh, North Carolina, United States

Site Status

Aultman Hospital

Canton, Ohio, United States

Site Status

Cleveland Cardiovascular Research Foundation

Fairview Park, Ohio, United States

Site Status

Abington Memorial Hospital

Abington, Pennsylvania, United States

Site Status

Presbyterian University of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Greenville Hospital Systems

Greenville, South Carolina, United States

Site Status

Avera Heart Hospital of South Dakota

Sioux Falls, South Dakota, United States

Site Status

Cardiovascular Associates, PC

Kingsport, Tennessee, United States

Site Status

Methodist Dallas Medical Center

Dallas, Texas, United States

Site Status

Texas Cardiac Center

Lubbock, Texas, United States

Site Status

South Texas Cardiovascular Consultants

San Antonio, Texas, United States

Site Status

Trinity Mother Frances Hospital

Tyler, Texas, United States

Site Status

Clear Lake Regional Medical Center

Webster, Texas, United States

Site Status

LDS Hospital

Salt Lake City, Utah, United States

Site Status

INOVA Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Hope Heart Institute

Bellevue, Washington, United States

Site Status

St. Peters Hospital

Olympia, Washington, United States

Site Status

St Mary's Hospital

Huntington, West Virginia, United States

Site Status

Care Foundation, Inc.

Wausau, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. JACC Cardiovasc Interv. 2010 Jul;3(7):742-50. doi: 10.1016/j.jcin.2010.04.012.

Reference Type DERIVED
PMID: 20650436 (View on PubMed)

Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, Rogers EW, Breall JA, Lewis DH, Song A, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS; ARRIVE 1 and ARRIVE 2 Participating Physicians. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv. 2009 Aug;2(4):285-93. doi: 10.1161/CIRCINTERVENTIONS.109.852178.109.852178. Epub 2009 Jul 22.

Reference Type DERIVED
PMID: 20031730 (View on PubMed)

Lasala JM, Cox DA, Lewis SJ, Tadros PN, Haas RC, Schweiger MJ, Chhabra A, Untereker WJ, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS. Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention. 2009 May;5(1):67-77. doi: 10.4244/eijv5i1a11.

Reference Type DERIVED
PMID: 19577985 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S2021

Identifier Type: -

Identifier Source: org_study_id